Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease: Clinical Evidence and Potential Adverse Events.

Q2 Medicine

Clinical Diabetes Pub Date : 2024-09-20 eCollection Date: 2025-01-01 DOI:10.2337/cd24-0036

Ashish Upadhyay, Lalarukh Haider

引用次数: 0

Abstract

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) globally and is associated with an increased risk of developing cardiovascular disease (CVD). DKD management requires a multipronged approach to decrease the progression of CKD and CVD. Mineralocorticoid receptor antagonists (MRAs) added to renin-angiotensin-aldosterone system blockade and sodium-glucose cotransporter 2 inhibitor therapy reduce the incidence of cardiovascular outcomes and progression of CKD. This review examines the cardiorenal benefits of MRAs and summarizes evidence on potential risks for acute kidney injury, hyperkalemia, and sexual dysfunction for steroidal and nonsteroidal MRAs.

查看原文本刊更多论文

糖皮质激素受体拮抗剂治疗糖尿病肾病：临床证据和潜在不良事件。

糖尿病肾病（DKD）是全球慢性肾脏疾病（CKD）的主要原因，并与发生心血管疾病（CVD）的风险增加有关。DKD管理需要多管齐下的方法来减少CKD和CVD的进展。矿盐皮质激素受体拮抗剂（MRAs）加入肾素-血管紧张素-醛固酮系统阻断和钠-葡萄糖共转运蛋白2抑制剂治疗可降低心血管结局的发生率和CKD的进展。本文综述了MRAs对心脏肾脏的益处，并总结了类固醇和非类固醇MRAs对急性肾损伤、高钾血症和性功能障碍的潜在风险的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Diabetes Medicine-Internal Medicine

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.